GTBP

GT Biopharma, Inc.

8 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 22

Nasdaq granted a 180-day extension to regain compliance with minimum bid price requirements.

regulatory action

40%

bearishMay 22

Extended compliance window increases likelihood of dilutive actions to support share price.

dilution risk

60%

neutralMay 22

Nasdaq granted a 180-day extension to regain compliance with minimum bid price requirements.

regulatory action

40%

bearishMay 22

Extended compliance window increases likelihood of dilutive actions to support share price.

dilution risk

60%

neutralMay 22

Nasdaq granted a 180-day extension to regain compliance with minimum bid price requirements.

regulatory action

40%

bearishMay 22

Extended compliance window increases likelihood of dilutive actions to support share price.

dilution risk

60%

neutralMay 22

Nasdaq granted a 180-day extension to regain compliance with minimum bid price requirements.

regulatory action

40%

bearishMay 22

Extended compliance window increases likelihood of dilutive actions to support share price.

dilution risk

60%

neutralMay 22

Nasdaq granted a 180-day extension to regain compliance with minimum bid price requirements.

regulatory action

40%

bearishMay 22

Extended compliance window increases likelihood of dilutive actions to support share price.

dilution risk

60%

neutralMay 22

Nasdaq granted a 180-day extension to regain compliance with minimum bid price requirements.

regulatory action

40%

bearishMay 22

Extended compliance window increases likelihood of dilutive actions to support share price.

dilution risk

60%

bearishMay 15

Net loss increased significantly to $2.83M due to spiking SG&A expenses.

margin compression

70%

bullishMay 15

Raised $4.58M through Series L Preferred Stock and warrant exercises.

capital raise

50%

bearishMay 15

Facing potential Nasdaq delisting due to minimum bid price non-compliance.

regulatory action

80%

bearishMay 15

Massive overhang from 57M warrants and low-priced convertible preferred stock.

dilution risk

90%

bearishMay 15

Net loss increased significantly to $2.83M due to spiking SG&A expenses.

margin compression

70%

bullishMay 15

Raised $4.58M through Series L Preferred Stock and warrant exercises.

capital raise

50%

bearishMay 15

Facing potential Nasdaq delisting due to minimum bid price non-compliance.

regulatory action

80%

bearishMay 15

Massive overhang from 57M warrants and low-priced convertible preferred stock.

dilution risk

90%

Filing History

8-KMay 22, 2026

GT Biopharma has secured a temporary reprieve from Nasdaq, extending its deadline to regain compliance with the minimum bid price requirement until November 16, 2026. While the extension removes the immediate risk of a ticker change or move to the OTC markets, it places the company in a precarious position where it must generate a significant positive catalyst to drive the share price above $1.00 for ten consecutive business days. The outcome now depends on whether the company can deliver clinical or corporate milestones that outweigh the structural risks of its current valuation.

10-QMay 15, 2026

GT Biopharma's Q1 2026 filing presents a high-stakes trade-off between cutting-edge clinical potential and severe financial instability. On one hand, the company is successfully advancing its proprietary TriKE platform into human trials for solid tumors and leukemias, potentially unlocking a massive addressable market. The operational shift toward camelid nanobodies represents a genuine scientific evolution that could differentiate the company from competitors in the immuno-oncology space. However, these scientific milestones are clouded by a balance sheet that appears designed for dilution. The combination of a going-concern warning, pending Nasdaq delisting, and a cascade of litigation creates a risk profile that may outweigh the clinical upside for many investors. The company's survival depends entirely on its ability to secure additional financing or produce an undeniable clinical win that attracts a strategic partner before its remaining cash is exhausted.